Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain

Table 2

Baseline to follow-up scores.

	Baseline	Followup	𝑃 value
VAS score	8.20±1.53	5.80±2.04	𝑃<0.001^∗
NPSI total score	5.2±1.5	3.8±2.1	𝑃: 0.025*
(i) Burning	7.2±2.7	5.6±3.2	𝑃: 0.063
(ii) Pressing	5.4±2.9	4.0±3.0	𝑃: 0.073
(iii) Paroxysmal pain	5.6±3.1	4.0±3.0	𝑃: 0.061
(iv) Evoked pain	3.7±2.3	3.0±2.2	𝑃: 0.279
(v) Paresthesia/dysesthesia	5.9±2.6	3.6±2.9	𝑃: 0.003*
EQ-5D score	−0.30±0.65	0.50±0.34	𝑃<0.001^∗

A significant improvement was observed in the VAS and NPSI scores between baseline and followup. Moreover, the NPSI subscores showed a highly significant improvement for the paresthesia/dysesthesia subscore and a trend towards amelioration for the other subscores.
VAS: Visual Analogue Scale; NPSI: Neuropathic Pain Symptom Inventory; EQ-5D: health questionnaire five dimensions.
∗Indicates the statistical significance (𝑃 value < 0.05).